Hemp-derived cannabinoids for menopause and perimenopause symptom relief
Effects of Hemp-Derived Cannabinoids on Menopause Symptoms
This will try hemp-derived cannabinoids versus placebo to see if they reduce physical and psychological symptoms in women aged 40–60 going through perimenopause or menopause.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 104 (estimated) |
| Ages | 40 Years to 60 Years |
| Sex | Female |
| Sponsor | Washington State University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Pullman, Washington) |
| Trial ID | NCT07393672 on ClinicalTrials.gov |
What this trial studies
This randomized, double-blind, placebo-controlled 3-month trial tests hemp-derived minor cannabinoids (for example CBG and CBD) on symptoms of menopause and perimenopause in women aged 40–60. Participants complete an online screen, provide consent via an initial Zoom visit, and perform baseline cognitive tests before receiving product shipped directly from the manufacturer. Eligible participants are randomized to active cannabinoids or placebo and are asked to abstain from regular cannabis and avoid changing other medications or supplements during the study. Symptom reports and cognitive outcomes are collected remotely over the study period to compare active treatment with placebo.
Who should consider this trial
Good fit: Women designated female at birth aged 40–60 who are perimenopausal or menopausal, are not regular cannabis users, are not taking excluded psychotropic medications, can use Zoom and a smartphone, and are willing to receive shipped study product are ideal candidates.
Not a fit: People who are pregnant or breastfeeding, have current severe depression or suicidality, psychosis or a family history of psychosis, are taking antidepressant/antipsychotic medications, or cannot abstain from other cannabis use are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, the cannabinoids could reduce menopausal physical and psychological symptoms and improve sleep and daily functioning for some women.
How similar studies have performed: Menopause-specific trials of cannabinoids are limited, and while some small studies and anecdotal reports suggest cannabinoids can help sleep, pain, and mood, this application for menopause remains relatively untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * designated female at birth * 40-60 years of age * able to give informed consent (no intellectual disability) * stable pharmacotherapeutic regimen, no change in the past 3 months * abstinent from regular cannabis use (\<1x/month) for past year, and willing to abstain from use for 3 months * abstinent for supplements, don't add any supplements (no changes in past 3 months) * own a smartphone * have access to Zoom on a secure, stable internet connection * perimenopausal or menopausal Exclusion Criteria: * currently taking anti-depressant, anti-anxiety, and/or antipsychotic medication * severe depression, neurovegetative symptoms, or current suicidality * psychosis or family history of psychosis * pregnant or breastfeeding * chemotherapy * hypotension * drug testing for work or other reasons * illicit drug use in past 3 months (cannabis not illicit) * heavy alcohol use (4 drinks more than 4x/week) * international/air travel planned for more than one week in the next 3 months * cocounut allergy
Where this trial is running
Pullman, Washington
- Washington State University, Dept of Psychology — Pullman, Washington, United States (Recruiting)
Study contacts
- Study coordinator: Carrie Cuttler, PhD
- Email: carrie.cuttler@wsu.edu
- Phone: (509) 592-0151
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.